Choice of Generic versus Brand-Name Antidepressants in a Regulated Prescription Drug Market: Evidence from Taiwan

被引:0
|
作者
Liu, Ya-Ming [1 ]
Ou, Huang-Tz [2 ]
Yang, Yen-Kuang [3 ]
机构
[1] Natl Cheng Kung Univ, Dept Econ, Tainan 701, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 701, Taiwan
[3] Natl Cheng Kung Univ, Dept Psychiat, Coll Med, Tainan 701, Taiwan
来源
关键词
PHARMACEUTICAL MARKET; PHYSICIAN; IMPACT;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: A health care system in which there is no separation between prescription and dispensation, combined with a regulated prescription drug market, leads to various generic substitution mechanisms for antidepressants. Aims of the Study: We investigated the determinants of generic versus brand-name antidepressant choices in a regulated prescription market where physicians both prescribe and dispense drugs. Methods: Using data from a sample of one million individuals selected randomly from the registry of National Health Insurance beneficiaries in 2010, and all claims for these one million enrollees between January 1997 and December 2011, we employed logistic regression to examine the choice of generic versus brand-name antidepressants in the Taiwanese prescription drug market. Results: Access to various antidepressant brands varies according to the accreditation level and type of ownership of the healthcare provider. Private healthcare providers and those with lower accreditation levels were more likely to prescribe generic antidepressants compared to their brand-name counterparts. The diversity of products and competition in the molecule market was positively associated with the probability of prescribing generic antidepressants. Discussion: In a regulated prescription drug market with no separation between prescription and dispensation, the substitution of generic antidepressant prescriptions in place of brand-name prescriptions is likely driven by drug and provider market characteristics, rather than by lowering costs. Implications for Healthcare Provision: The allocation of different types of ownership and accreditation levels of healthcare providers may lead to unequal access to various brands of antidepressants. Implications for Health Policies: Policies for improving the treatment of depression should take into account the structure of molecule and provider markets as important factors in determining the choice and utilization of antidepressants, in a healthcare system where physicians both prescribe and dispense drugs. Implications for Future Research: Other psychotropic drug classes should be investigated to explore the effect of molecule and provider characteristics on the utilization of various classes of medication.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 50 条
  • [41] Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data
    Farfan-Portet, Maria-Isabel
    Van de Voorde, Carine
    Vrijens, France
    Vander Stichele, Robert
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (03): : 301 - 313
  • [42] Renal Toxicity Caused by Brand-name Versus Generic Cisplatin: A Comparative Analysis
    Niho, Seiji
    Yamanaka, Takeharu
    Umemura, Shigeki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Goto, Koichi
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (04) : 390 - 395
  • [43] THE IMPACT OF MODIFICATIONS OF THE FORMULA FOR GENERIC DRUG PRESCRIPTION RATE ON THE SWITCH TO NEW BRAND-NAME DRUGS WITH SIMILAR THERAPEUTIC USES
    Shimizu, S.
    Imai, S.
    Ishikawa, K. B.
    Ikeda, S.
    Fushimi, K.
    VALUE IN HEALTH, 2014, 17 (07) : A499 - A499
  • [44] The Comparison of Brand-Name and Generic Formulations of Venlafaxine: A Therapeutic Drug Monitoring Analysis
    Unterecker, Stefan
    Proft, Florian
    Riederer, Peter
    Lauer, Martin
    Deckert, Juergen
    Pfuhlmann, Bruno
    THERAPEUTIC DRUG MONITORING, 2014, 36 (02) : 269 - 272
  • [45] Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
    Tsadok, Meytal A.
    Jackevicius, Cynthia A.
    Rahme, Elham
    Essebag, Vidal
    Eisenberg, Mark J.
    Humphries, Karin H.
    Tu, Jack V.
    Behlouli, Hassan
    Joo, Jennifer
    Pilote, Louise
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (12) : E817 - E823
  • [46] Exploration of approaches to adjusting brand-name drug prices in Mainland of China: based on comparison and analysis of some brand-name drug prices of Mainland and Taiwan, China
    Weng Geng
    Han Sheng
    Pu Run
    Wynn, Pan H. T.
    Shi Luwen
    CHINESE MEDICAL JOURNAL, 2014, 127 (12) : 2222 - 2228
  • [47] Are generic and brand-name statins clinically equivalent? Evidence from a real data-base
    Corrao, Giovanni
    Soranna, Davide
    Arfe, Andrea
    Casula, Manuela
    Tragni, Elena
    Merlino, Luca
    Mancia, Giuseppe
    Catapano, Alberico L.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (08) : 745 - 750
  • [48] Generic versus brand name: the other drug war
    McCormack, James
    Chmelicek, John T.
    CANADIAN FAMILY PHYSICIAN, 2014, 60 (10) : 911 - 911
  • [49] How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
    Beall, Reed F.
    Hardcastle, Lorian
    Clement, Fiona
    Hollis, Aidan
    HEALTH POLICY, 2019, 123 (12) : 1251 - 1258
  • [50] Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
    Bosak, Magdalena
    Slowik, Agnieszka
    Turaj, Wojciech
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2287 - 2291